I 

112TH CONGRESS 

1ST SESSION H. R. 2951 

To intensify stem cell research showing evidence of substantial clinical benefit 

to patients, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

SEPTEMBER 15, 2011 

Mr. FORBES (for himself, Mr. LIPINSKI, Mr. SMITH of New Jersey, Mr. 

COFFMAN of Colorado, Mr. FRANKS of Arizona, Mr. LAMBORN, Mr. HENSARLING, Mrs. SCHMIDT, Mr. WESTMORELAND, Mr. PITTS, Mrs. BLACKBURN, Mrs. ELLMERS, Mr. LATTA, Mr. CANSECO, Mr. PENCE, Mr. 

NUNNELEE, Mr. WITTMAN, Mr. MILLER of Florida, Mr. HUELSKAMP, 

and Mr. FLEMING) introduced the following bill; which was referred to 

the Committee on Energy and Commerce 

A BILL 

To intensify stem cell research showing evidence of substantial clinical benefit to patients, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Patients First Act of 

5 2011’’. 

6 SEC. 2. PURPOSES. 

7 It is the purpose of this Act to— 


tjames on DSK6SPTVN1PROD with BILLS
2 

•HR 2951 IH

1 (1) intensify research that may result in im2 proved understanding of or treatments for diseases 

3 and other adverse health conditions; 

4 (2) promote research and human clinical trials 

5 using stem cells that are ethically obtained and show 

6 evidence of providing clinical benefit for human pa7 tients; and 

8 (3) promote the derivation of pluripotent stem 

9 cell lines without the creation of human embryos for 

10 research purposes and without the destruction or 

11 discarding of, or risk of injury to, a human embryo. 

12 SEC. 3. HUMAN STEM CELL RESEARCH AND THERAPY. 

13 (a) AUTHORIZATION.—Part B of title IV of the Pub14 lic Health Service Act (42 U.S.C. 284 et seq.) is amended 

15 by inserting after section 409I the following: 

16 ‘‘SEC. 409K. HUMAN STEM CELL RESEARCH AND THERAPY. 

17 ‘‘(a) IN GENERAL.—The Secretary shall conduct and 

18 support basic and applied research to develop techniques 

19 for the isolation, derivation, production, testing, and 

20 human clinical use of stem cells that may result in im21 proved understanding of or treatments for diseases and 

22 other adverse health conditions, including pluripotent stem 

23 cells that have the flexibility of embryonic stem cells 

24 (whether or not such pluripotent stem cells have an embry25 onic source), prioritizing research with the greatest potenVerDate Mar 15 2010 04:27 Sep 17, 2011 Jkt 099200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H2951.IH H2951

tjames on DSK6SPTVN1PROD with BILLS
3 

•HR 2951 IH

1 tial for near-term clinical benefit in human patients, pro2 vided that such isolation, derivation, production, testing, 

3 or use will not involve— 

4 ‘‘(1) the creation of a human embryo for re5 search purposes; 

6 ‘‘(2) the destruction of or discarding of, or risk 

7 of injury to, a living human embryo; or 

8 ‘‘(3) the use of any stem cell, the derivation or 

9 provision of which would be inconsistent with the 

10 standards established in paragraph (1) or (2). 

11 ‘‘(b) GUIDELINES.—Not later than 90 days after the 

12 date of the enactment of this section, the Secretary, after 

13 consultation with the Director of NIH, shall issue final 

14 guidelines implementing subsection (a) to ensure that any 

15 research (including any clinical trial) supported under 

16 subsection (a)— 

17 ‘‘(1) is clearly consistent with the standards es18 tablished in subsection (a) if conducted using human 

19 cells, as demonstrated by animal trials or other sub20 stantial evidence; and 

21 ‘‘(2) is prioritized in terms of potential for 

22 near-term clinical benefit in human patients, as indi23 cated by substantial evidence from basic research or 

24 by substantial clinical evidence which may include 

25 but is not limited to— 


tjames on DSK6SPTVN1PROD with BILLS
4 

•HR 2951 IH

1 ‘‘(A) evidence of improvement in one or 

2 more human patients suffering from illness or 

3 injury, as documented in reports by professional 

4 medical or scientific associations or in peer-re5 viewed medical or scientific literature; or 

6 ‘‘(B) approval for use in human trials by 

7 the Food and Drug Administration. 

8 ‘‘(c) DEFINITIONS.—In this section: 

9 ‘‘(1) HUMAN EMBRYO.—The term ‘human em10 bryo’ includes any organism, not protected as a 

11 human subject under part 46 of title 45, Code of 

12 Federal Regulations, as of the date of the enactment 

13 of this section, that is derived by fertilization, par14 thenogenesis, cloning, or any other means from one 

15 or more human gametes or human diploid cells. 

16 ‘‘(2) RISK OF INJURY.—The term ‘risk of in17 jury’ means subjecting a human embryo to risk of 

18 injury or death greater than that allowed for re19 search on fetuses in utero under section 46.204(b) 

20 of title 45, Code of Federal Regulations (or any suc21 cessor regulation), or section 498(b) of this Act.’’. 

22 (b) PRIORITY SETTING; REPORTS.—Section 492 of 

23 the Public Health Service Act (42 U.S.C. 289a) is amend24 ed by adding at the end the following: 


tjames on DSK6SPTVN1PROD with BILLS
5 

•HR 2951 IH

1 ‘‘(d)(1) With respect to human stem cell research, the 

2 Secretary, acting through the Director of NIH, shall give 

3 priority to conducting or supporting research in accord4 ance with section 409K. 

5 ‘‘(2) At the end of fiscal year 2012 and each subse6 quent fiscal year, the Secretary shall submit to the Con7 gress a report outlining the number of research proposals 

8 under section 409K that were peer reviewed, a summary 

9 and detailed list of all such research proposals that were 

10 not funded, and an explanation of why the proposals did 

11 not merit funding. The reports under this paragraph shall 

12 be in addition to the reporting on stem cell research in13 cluded in the biennial report required by section 403.’’. 

14 (c) BIENNIAL REPORTS.—Section 403(a)(5) of the 

15 Public Health Service Act (42 U.S.C. 283(a)(5)) is 

16 amended— 

17 (1) by redesignating subparagraph (L) as sub18 paragraph (M); and 

19 (2) by inserting after subparagraph (K) the fol20 lowing: 

21 ‘‘(L) Stem cells.’’. 

Æ 


tjames on DSK6SPTVN1PROD with BILLS